Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000

Archives of Neurology

Volumn 58, Issue 12, 2001, Pages 2009-2013

  Grotta, James C ^a,b   Scott Burgin, W ^a   El Mitwalli, Ashraf ^a   Long, Megan ^a   Campbell, Morgan ^a   Morgenstern, Lewis B ^a   Malkoff, Marc ^a   Alexandrov, Andrei V ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ADULT; AGED; ARTICLE; BOLUS INJECTION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCORING SYSTEM;

EID: 20644462132     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.58.12.2009     Document Type: Article

References (23)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischaemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Adams HP Jr, Brott TG, Furlan AJ, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke: a statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Circulation. 1996;94:1167-1174.
3. Chiu D, Krieger D, Villar-Cordova C, et al. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke. 1998;29:18-22.
4. Kwiatkowski TG, Libman RB, Frankel M, et al, for the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med. 1999;340:1781-1787.
5. Schmülling S, Grond M, Rudolf J, Heiss WD. One-year follow-up in acute stroke patients treated with rtPA in clinical routine. Stroke. 2000;31:1552-1554.
6. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000;283:1145-1150.
7. Tanne D, Bates VE, Verro P, and the t-PA Stroke Survey Group. Initial clinical experience with IV tissue plaminogen activator for acute ischemic stroke: a multicenter survey. Neurology. 1999;53:424-427.
8. Katzan IL, Furlan AJ, Lloyd LE, et al. Use of tissue-type plasminogen activator for treatment of acute stroke: the Cleveland area experience. JAMA. 2000;283: 1151-1158.
9. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. A systems approach to immediate evaluation and management of hyperacute stroke: experience at eight centers and implications for community practice and patient care. Stroke. 1997;28:1530-1540.
10. Williams LS, Yilmaz EY, Lopez-Yunez AM. Retrospective assessment of initial stroke severity with the NIH Stroke Scale. Stroke. 2000;31:858-862.
11. Gordon DL, Bendixen BH, Adams HP Jr, Clarke W, Kappelle LJ, Woolson RF, for the TOAST Investigators. Interphysician agreement in the diagnosis of subtypes of acute ischemic stroke: implications for clinical trials. Neurology. 1993;43: 1021-1027.
12. Wein TH, Staub L, Felberg RA, et al. Activation of emergency medical services for acute stroke in a nonurban population: the T. L. L. Temple Foundation Stroke Project. Stroke. 2000;31:1925-1928.
13. Luepker RV, Raczynski JM, Osganian S, et al. Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease: the Rapid Early Action for Coronary Treatment (REACT) Trial. JAMA. 2000;284:60-67.
14. Alberts MJ, Hademenos G, Latchaw RE, et al, for the Brain Attack Coalition. Recommendations for the establishment of primary stroke centers [review]. JAMA. 2000;283:3102-3109.
15. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke. 1997;28:2109-2118.
16. Hacke W, Kaste M, Fieschi C, et al, for the European Cooperative Acute Stroke Study (ECASS). Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA. 1995;274:1017-1025.
17. Hacke W, Kaste M, Fieschi C, et al, for the Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Lancet. 1998;352:1245-1251.
18. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of incidence and risk factors. Stroke. 1999;30:2513-2516.
19. Sacco RL, Ellenberg JH, Mohr JP, et al. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol. 1989;25:382-390.
20. Chamorro A, Sacco RL, Mohr JP, et al. Clinical-computed tomographic correlations of lacunar infarction in the Stroke Data Bank. Stroke. 1991;22:175-181.
21. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology. 2000;55:1649-1655.
22. Marler JR, Jones PW, Emr M, eds. Proceedings From a National Symposium on Rapid Identification and Treatment of Acute Stroke. Bethesda, Md: National Institues of Health/NINDS; 1997.
23. Hill MD, Barber PA, Demchuk AM, et al. Building a "brain attack" team to administer thrombolytic therapy for acute ischemic stroke. CMAJ. 2000;162:1589-1593.